Human papillomavirus 9

The nine-valent HPV vaccine is used to prevent cervical cancer caused by human papillomavirus (HPV) infection and can prevent more than 90% of cervical cancer. The vaccine was approved for sale abroad in 2014. On April 28, 2018, the National Medical Products Administration approved the sale of the nine-valent HPV vaccine for the prevention of cervical cancer in my country. Vaccination is the primary prevention, and screening is the secondary prevention, and both are equally important.

Therefore, cervical cancer screening measures cannot be relaxed just because of vaccination.

The nine-valent HPV vaccine approved for sale in my country is suitable for women aged 16 to 26. Often included in this age group, the actual basis comes from three aspects:

1. The clinical trial age for this vaccine is 16 to 26 years old. In this age group, the vaccine's overseas clinical trial data and its protective effectiveness against sustained infection in the Asia-Pacific population suggest that its benefits outweigh the risks.

2. In our country, the probability of females aged 9 to 15 years old surviving is very low. Only immunity bridging experiments were conducted for those aged 9 to 15 years old, and the clinical trial data information on the Chinese population in the Asia-Pacific region was limited.

3. Women over 26 years old are very likely to have a history of virus exposure, and there is no evidence to prove that the vaccine has a protective effect on exposed groups of this age group.

Interference measures

1. Before getting vaccinated, be sure to carefully understand the effectiveness, safety factor (including possible side effects) and contraindications of the vaccine.

2. After vaccination, you must stay for observation for 15 to 30 minutes and leave only after there are no other reactions.

3. Once side effects occur, cooperate closely with the vaccinators to handle the response.